CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Providing Alternative to Inhalation via Patented Oral Drug-Delivery Technology

British Columbia-based, biodelivery technology developer Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is committed to the idea that better alternative methods for drug delivery exist than inhalation. A recent article discussing the company reads, “Swallowed medications have historically been slower to provide effective action than inhaled ones, leading substance users looking for a quick fix to lean toward the latter. But the deleterious and deadly consequences of smoking tobacco products have been publicly acknowledged for decades, though hardly stemming the tide of nicotine addiction as one generation succeeds another. . . . The continued preference for the rapid delivery of inhaled drug substances has led many researchers to seek alternatives beyond deterrence campaigns. DehydraTECH’s newest formulation was recently shown to deliver 811% more CBD into the bloodstream than generic industry control formulations, nearly doubling the capacity of existing DehydraTECH technology. It was additionally shown to deliver 1,937% more CBD across the blood-brain barrier into brain tissue than generic industry-control formulations and 487% more than the original DehydraTECH technology (http://cnw.fm/89Soz).”

To view the full article, visit http://cnw.fm/95Fyc

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual-property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s